Cel Sci (CVM) Assets (2010 - 2026)
Cel Sci (CVM) posted Assets of $17.7 million for Q1 2026, down 22.66% sequentially from $22.9 million in Q4 2025, and down 18.8% YoY from $21.8 million in Q1 2025.
Cel Sci (CVM) Assets (2010 - 2026) Analysis & Trends
Cel Sci has reported Assets for 16 years, with the latest figure at $17.7 million in Q1 2026.
- Quarterly Assets fell 18.8% year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (down 18.8% YoY) and the FY2025 annual result came in at $28.2 million, up 4.31% from the prior year.
- Assets slipped to $17.7 million in Q1 2026 per CVM's latest filing, from $22.9 million in the prior quarter.
- Over five years, Assets peaked at $64.2 million in Q1 2022 and troughed at $17.7 million in Q1 2026.
- A 5-year average of $33.2 million and a median of $28.7 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets surged 32.66% in 2022, then plunged 43.19% in 2023.
- Over 5 years, Assets stood at $44.6 million in 2022, then sank by 35.57% to $28.7 million in 2023, then decreased by 10.49% to $25.7 million in 2024, then decreased by 10.91% to $22.9 million in 2025, then dropped by 22.66% to $17.7 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $17.7 million, $22.9 million, and $28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 21.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.71 Mn |
| Dec 31, 2025 | 22.89 Mn |
| Sep 30, 2025 | 28.16 Mn |
| Jun 30, 2025 | 20.34 Mn |
| Mar 31, 2025 | 21.81 Mn |
| Dec 31, 2024 | 25.70 Mn |
| Sep 30, 2024 | 26.99 Mn |
| Jun 30, 2024 | 24.07 Mn |
| Mar 31, 2024 | 30.05 Mn |
| Dec 31, 2023 | 28.71 Mn |
| Sep 30, 2023 | 30.53 Mn |
| Jun 30, 2023 | 32.32 Mn |
| Mar 31, 2023 | 38.20 Mn |
| Dec 31, 2022 | 44.56 Mn |
| Sep 30, 2022 | 50.52 Mn |
| Jun 30, 2022 | 56.89 Mn |
| Mar 31, 2022 | 64.16 Mn |
| Dec 31, 2021 | 69.67 Mn |
| Sep 30, 2021 | 75.87 Mn |
| Jun 30, 2021 | 79.64 Mn |